

Anna Ehinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2024412/publications.pdf>

Version: 2024-02-01

56
papers

4,589
citations

236925

25
h-index

243625

44
g-index

62
all docs

62
docs citations

62
times ranked

8753
citing authors

#	ARTICLE	IF	CITATIONS
1	Difficulties in diagnostics of lung tumours in biopsies: an interpathologist concordance study evaluating the international diagnostic guidelines. <i>Journal of Clinical Pathology</i> , 2022, 75, 302-309.	2.0	7
2	Abstract P2-08-11: How reliable are biomarkers assessed on a core needle biopsy? A study of paired core needle biopsies and surgical specimens in early breast cancer. <i>Cancer Research</i> , 2022, 82, P2-08-11-P2-08-11.	0.9	0
3	The Prognostic Role of Intratumoral Stromal Content in Lobular Breast Cancer. <i>Cancers</i> , 2022, 14, 941.	3.7	5
4	Development of Training Materials for Pathologists to Provide Machine Learning Validation Data of Tumor-Infiltrating Lymphocytes in Breast Cancer. <i>Cancers</i> , 2022, 14, 2467.	3.7	4
5	Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. <i>Modern Pathology</i> , 2022, 35, 1362-1369.	5.5	18
6	Abstract 460: Tools for collecting pathologist annotations and understanding interobserver variability. <i>Cancer Research</i> , 2022, 82, 460-460.	0.9	0
7	Molecular analyses of triple-negative breast cancer in the young and elderly. <i>Breast Cancer Research</i> , 2021, 23, 20.	5.0	23
8	Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 26.	5.0	19
9	Variability in Breast Cancer Biomarker Assessment and the Effect on Oncological Treatment Decisions: A Nationwide 5-Year Population-Based Study. <i>Cancers</i> , 2021, 13, 1166.	3.7	31
10	Preexisting Somatic Mutations of Estrogen Receptor Alpha (<i>ESR1</i>) in Early-Stage Primary Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab028.	2.9	20
11	An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5557-5565.	7.0	26
12	Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions. <i>Nature Communications</i> , 2021, 12, 6012.	12.8	140
13	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	5.2	112
14	Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 28.	5.2	25
15	Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. <i>Nature Communications</i> , 2020, 11, 3747.	12.8	53
16	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	5.2	106
17	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	4.5	142
18	Pan-cancer analysis of whole genomes. <i>Nature</i> , 2020, 578, 82-93.	27.8	1,966

#	ARTICLE	IF	CITATIONS
19	The mutational landscape of the <scp>SCAN</scp> â€œ realâ€œworld primary breast cancer transcriptome. EMBO Molecular Medicine, 2020, 12, e12118.	6.9	36
20	Abstract P1-18-10: Preoperative treatment of HER2-positive breast cancer in South Sweden. A retrospective, comprehensive survey of neo-adjuvant treated HER2-positive breast cancer in the SCAN-B project 2010-2017. , 2020, , .		0
21	Defining the mutational landscape of 3,217 primary breast cancer transcriptomes through large-scale RNA-seq within the Sweden Cancerome Analysis Network: Breast Project (SCAN-B; NCT03430492).. Journal of Clinical Oncology, 2020, 38, 518-518.	1.6	2
22	Abstract CT074: Pre-existing ESR1 mutations in early-stage primary breast cancer predict failure of endocrine therapy and poor survival. , 2020, , .		1
23	Abstract P5-02-01: Analytical validation and prognostic potential of an automated digital scoring protocol for Ki67: An International Ki67 Working Group study. , 2020, , .		0
24	Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort. Clinical Cancer Research, 2019, 25, 6368-6381.	7.0	37
25	Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series. Scientific Reports, 2019, 9, 12184.	3.3	39
26	Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer. Breast Cancer Research and Treatment, 2019, 178, 459-467.	2.5	23
27	Refinement of breast cancer molecular classification by miRNA expression profiles. BMC Genomics, 2019, 20, 503.	2.8	75
28	Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. Histopathology, 2019, 75, 225-235.	2.9	74
29	Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nature Medicine, 2019, 25, 1526-1533.	30.7	218
30	Expression of HIF-1Î± is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer. PLoS ONE, 2019, 14, e0226150.	2.5	52
31	Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative. British Journal of Surgery, 2018, 105, e158-e168.	0.3	32
32	Clinical Value of RNA Sequencingâ€œBased Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Networkâ€œBreast Initiative. JCO Precision Oncology, 2018, 2, 1-18.	3.0	101
33	Stability of oestrogen and progesterone receptor antigenicity in formalinâ€œfixed paraffinâ€œembedded breast cancer tissue over time. Apmis, 2018, 126, 746-754.	2.0	4
34	Abstract P4-09-03: On the development and clinical value of RNA-sequencing-based classifiers for prediction of the five conventional breast cancer biomarkers: A report from the population-based multicenter SCAN-B study. , 2018, , .		1
35	Abstract P2-02-09: Breast cancer subtype distribution and circulating tumor DNA in response to neoadjuvant chemotherapy: Experiences from a preoperative cohort within SCAN-B. , 2018, , .		0
36	Abstract P2-03-01: Analytical validation of a standardized scoring protocol for Ki67 assessed on breast excision whole sections: An international multicenter collaboration. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
37	Abstract P1-06-01: Putting multigene signatures to the test: Prognostic assessment in population-based contemporary clinical breast cancer. , 2018, , .		0
38	Abstract P3-02-02: Concordance between immunohistochemical and gene-expression based subtyping of early breast cancer using core needle biopsies and surgical specimens - experices from SCAN-B. , 2018, , .		0
39	Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. Acta Oncol ³ gica, 2017, 56, 68-74.	1.8	51
40	Abstract P1-07-17: The SCAN-B study: 5-year summary of a large-scale population-based prospective breast cancer translational genomics platform covering a wide geography of Sweden (NCT02306096). , 2017, , .		0
41	Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer. PLoS ONE, 2016, 11, e0150977.	2.5	9
42	The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Medicine, 2015, 7, 20.	8.2	129
43	Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy. European Journal of Cancer, 2015, 51, 2304-2313.	2.8	8
44	Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing. Breast Cancer Research, 2015, 17, 102.	5.0	30
45	Abstract P6-08-43: Histological grade provides significant prognostic information in the discrimination between luminal A-like and luminal B-like HER-2 normal subtypes of breast cancer according to St Gallen 2013. , 2015, , .		0
46	Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. ELife, 2014, 3, .	6.0	318
47	Processed pseudogenes acquired somatically during cancer development. Nature Communications, 2014, 5, 3644.	12.8	86
48	Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. Science, 2014, 345, 1251343.	12.6	348
49	Acute pancreatitis evoked by small-cell lung carcinoma metastases and detected by endoscopic ultrasound. Endoscopy, 2012, 44, E45-E46.	1.8	3
50	The G protein-coupled estrogen receptor 1 (GPER/GPR30) does not predict survival in patients with ovarian cancer. Journal of Ovarian Research, 2012, 5, 9.	3.0	47
51	Changing clinical presentation of angiosarcomas after breast cancer: from late tumors in edematous arms to earlier tumors on the thoracic wall. Breast Cancer Research and Treatment, 2010, 122, 883-887.	2.5	30
52	G protein-coupled estrogen receptor 1 (GPER, GPR 30) in normal human endometrium and early pregnancy decidua. Molecular Human Reproduction, 2010, 16, 743-751.	2.8	55
53	Histamine uptake by human endometrial cells expressing the organic cation transporter EMT and the vesicular monoamine transporter-2. Molecular Human Reproduction, 2006, 12, 483-489.	2.8	13
54	Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle. Molecular Human Reproduction, 2004, 10, 655-663.	2.8	38

#	ARTICLE	IF	CITATIONS
55	Paracrine Stimulation of Capillary Endothelial Cell Migration by Endometrial Tissue Involves Epidermal Growth Factor and Is Mediated Via Up-Regulation of the Urokinase Plasminogen Activator Receptor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1724-1730.	3.6	3
56	Breast metastases from pancreatic and ovarian carcinoma. <i>Diagnostic Cytopathology</i> , 1999, 21, 154-155.	1.0	7